SA PRO
Free Account
Themes
PTC Inc.PTCNASDAQ
Loading
OverviewIntelligenceChartsNewsFundamentalsEarningsAnalysts

Latest News

PTC Will Participate in Upcoming Investor Conferences
prnewswire.com

PTC Will Participate in Upcoming Investor Conferences

BOSTON, Feb. 27, 2026 /PRNewswire/ -- PTC (Nasdaq: PTC) today announced that it will participate in the following conferences. What: KeyBanc Capital Markets Emerging Technology Summit When: 1x1's on Tuesday, March 3, 2026  What: Morgan Stanley Technology, Media & Telecom Conference When: Wednesday, March 4, 2026 at 4:05pm PST  What: BofA Securities 33rd Annual Industrials, Transportation & Airlines Key Leaders Conference When: 1x1's on Tuesday, May 12, 2026 What: J.P.

PTC's Onshape Launches Cloud-Native Model-Based Definition Capabilities
prnewswire.com

PTC's Onshape Launches Cloud-Native Model-Based Definition Capabilities

Introduces the only cloud-native MBD capability built into the core modeling experience, fully integrated within CAD and PDM Creates a single, always-up-to-date product definition by embedding manufacturing information directly in the live 3D model Improves collaboration and change control across engineering and manufacturing BOSTON, Feb. 26, 2026 /PRNewswire/ -- PTC (NASDAQ: PTC) today announced the release of a fully cloud-native Model-Based Definition (MBD) capability, built directly into its Onshape® computer-aided design (CAD) and product data management (PDM) platform. The new capability allows engineering teams to add manufacturing information directly into the 3D model early in the design process, enabling clearer design intent, fewer handoffs, and improved efficiency across design, documentation, manufacturing, and quality.

PTC Therapeutics: Sephience As A Major Growth Driver
seekingalpha.com

PTC Therapeutics: Sephience As A Major Growth Driver

PTC Therapeutics is transitioning its growth engine from legacy drugs to new launches like Sephience, targeting rare genetic diseases with high unmet need. Pipeline catalysts, notably Votoplam for Huntington's disease and Vatiquinone for Friedreich's ataxia, offer significant upside but carry clinical trial risks. PTCT's competitive edge lies in its oral small molecule platform, collaborative development model, and strong pricing power in ultra-rare disease markets.

Aurora Investment Counsel Sells 5,716 Shares of PTC Inc. $PTC
defenseworld.net

Aurora Investment Counsel Sells 5,716 Shares of PTC Inc. $PTC

Aurora Investment Counsel decreased its position in PTC Inc. (NASDAQ: PTC) by 70.5% during the undefined quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 2,395 shares of the technology company's stock after selling 5,716 shares during the quarter. Aurora Investment Counsel's holdings in PTC

PTC Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results
prnewswire.com

PTC Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results

– Full-year 2025 product and royalty revenue of $831M, exceeding guidance – – Strong Sephience™ (sepiapterin) uptake since 2H 2025 launch with fourth quarter and 2025 revenue of $92M and $111M, respectively – – Cash of $1.95B as of December 31, 2025 – WARREN, N.J., Feb. 19, 2026 /PRNewswire/ -- PTC Therapeutics, Inc., (NASDAQ: PTCT) today announced a corporate update and financial results for the fourth quarter and full year ending December 31, 2025.

PTC Therapeutics Provides Regulatory Update on Translarna™
prnewswire.com

PTC Therapeutics Provides Regulatory Update on Translarna™

WARREN, N.J., Feb. 12, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that it has withdrawn the New Drug Application (NDA) resubmission for Translarna™ (ataluren) for the treatment of nonsense mutation Duchenne muscular dystrophy (DMD) following U.S. Food and Drug Administration (FDA) feedback on the application review.

PTC FlexPLM to Strengthen SPG Company's Licensed Product Operations
prnewswire.com

PTC FlexPLM to Strengthen SPG Company's Licensed Product Operations

Addresses performance, data consistency, and workflow challenges that slow product development and impact downstream teams Enables faster, more collaborative product execution with a cloud-based PLM solution built to support future growth BOSTON, Feb. 12, 2026 /PRNewswire/ -- PTC (NASDAQ: PTC) today announced that SPG Company, a global leader in licensed product design, development, manufacturing, and distribution, has selected PTC's FlexPLM® retail product lifecycle management (PLM) solution to modernize and support its end-to-end product lifecycle operations. With FlexPLM, SPG will replace its legacy PLM system with a scalable, cloud-based platform designed to support faster development cycles and more consistent product data.

Drake & Associates LLC Buys New Position in PTC Inc. $PTC
defenseworld.net

Drake & Associates LLC Buys New Position in PTC Inc. $PTC

Drake and Associates LLC purchased a new position in shares of PTC Inc. (NASDAQ: PTC) during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 9,647 shares of the technology company's stock, valued at approximately $1,833,000. Other hedge funds have also made

Code Rebel (OTCMKTS:CDRBQ) and PTC (NASDAQ:PTC) Critical Analysis
defenseworld.net

Code Rebel (OTCMKTS:CDRBQ) and PTC (NASDAQ:PTC) Critical Analysis

Code Rebel (OTCMKTS:CDRBQ - Get Free Report) and PTC (NASDAQ: PTC - Get Free Report) are both computer and technology companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, risk, analyst recommendations, valuation, institutional ownership and profitability. Institutional and Insider Ownership 95.1% of PTC

PTC Q1 Earnings Call Highlights
defenseworld.net

PTC Q1 Earnings Call Highlights

PTC (NASDAQ: PTC) executives said the company delivered a "solid" start to fiscal 2026, pointing to steady annual recurring revenue (ARR) growth, expanding free cash flow, and what they described as improving demand capture tied to its "Intelligent Product Lifecycle" strategy. On the company's fiscal first-quarter earnings call, CEO Neil Barua said PTC grew constant-currency ARR

PTC ANNOUNCES FIRST FISCAL QUARTER 2026 RESULTS
prnewswire.com

PTC ANNOUNCES FIRST FISCAL QUARTER 2026 RESULTS

Strategic focus on Intelligent Product Lifecycle vision Solid execution in Q1'26 Constant currency ARR growth of 8.4%; 9.0% excluding Kepware and ThingWorx Operating and free cash flow growth of 13% Embedding AI across portfolio and building common AI infrastructure to drive customer adoption and value Executing on our $2 billion share repurchase authorization: $200 million of repurchases in Q1'26; expect to use net after-tax proceeds from the Kepware and ThingWorx divestiture for incremental repurchases; targeting repurchases of ~$1.115 billion to ~$1.315 billion in FY'26 BOSTON, Feb. 4, 2026 /PRNewswire/ -- PTC (NASDAQ: PTC) today reported financial results for its first fiscal quarter ended December 31, 2025. "PTC delivered solid financial results in Q1'26, driven by large deal volume and competitive displacements.

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance